THURSDAY, 30 JUNE, 2016 FRIDAY, 1 JULY 2016

Similar documents
Saturday, 8 September 2018 Treatment options and update on statin treatment Chair: M. Kayikcioglu, V. Kotsis How far should we lower LDL?

Saturday, 11th February 2017

18:00-19:00 Welcome Reception Exhibition Area

PRELIMINARY PROGRAM. 14:10-15:00 Session I: My Personal Experience CT/MR Chair: Herbert Frank Tulln, Austria Udo Hoffmann Boston, USA

October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany

Program Agenda. Ottawa Heart Research Conference (OHRC): Steadying the Future of Atrial Fibrillation. Thursday, June 2 nd (Day 1)

ESC/EAS GUIDELINES ON MANAGEMENT OF DYSLIPIDEMIAS IN CLINICAL PRACTICE

The TNT Trial Is It Time to Shift Our Goals in Clinical

Friday, March 1 st, 2019

Sunday, March 22, 2015

CLINICAL OUTCOME Vs SURROGATE MARKER

Core Curriculum for the Cardiovascular Clinician

Preliminary PROGRAM. Thursday October 5, :00 Welcome Herbert Frank Tulln, AT. Session I: 14:10 15:00 MY PERSONAL EXPERIENCE CT/CMR

Lipid Management 2013 Statin Benefit Groups

The Cardiac Patient from Birth to Adulthood February 2019 in Stockholm Sweden

EAS Congress Innsbruck Highlights: A programme to excite, inspire and inform!

18:00-19:00 Welcome Reception Exhibition Area

BREAKS NETWORKING EVENTS PARALLEL SESSIONS INDUSTRY SUPPORTED SESSIONS Academy of Autoimmunity SYMPOSIUM

CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS WITH DIABETES AND CVD

Pan American Heart Failure Congress (PAHF 2012) October 18 th -21 th 2012 Panama City, Panama

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

5 th Annual Meeting Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group November 15-17, 2012 Paris, France

Prof. Renata Cífková, MD, CSc.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Protecting the heart and kidney: implications from the SHARP trial

INDUSTRY SUPPORTED SESSIONS. Auditorium I Auditorium II Auditorium VIII Auditorium III Pavilion 3A Pavilion 3B. Academy of Autoimmunity

XXI Congress of the Cardiology Society of Serbia (CSS) Preliminary Programme Zlatibor, October, 2017

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy

Approach to Dyslipidemia among diabetic patients

4:30 p.m. Jack Vogel Memorial Lecture Evolution and Revolution in the Treatment of Valvular Heart Disease Dr. Mack

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY

INDUSTRY SUPPORTED SESSIONS. Auditorium I Auditorium II Auditorium VIII Auditorium III Pavilion 3A Pavilion 3B. Academy of Autoimmunity

EPNV-Montreux 2018: Preliminary Educational and Scientific Program

CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018

Modern Lipid Management:

Low-Carbohydrate Diets and All-Cause and Cause-Specific Mortality: A Population-based Cohort Study and Pooling Prospective Studies

To provide clinically relevant information about Clinical Nutrition.

Drug Class Prior Authorization Criteria PCSK9 Inhibitors

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

ISRAELI NEUROENDOCRINE TUMORS PROGRAM

Joint Congress PAFCIC Complex PCI meeting

PRELIMINARY PROGRAMME

DIABETES AND MACROVASCULAR DISEASE

Cholesterol Management Roy Gandolfi, MD

5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition

Review of guidelines for management of dyslipidemia in diabetic patients

Page 1. Disclosures. Background. No disclosures

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Safety Pharmacology Post Meeting Survey 2014

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

8 th EuroCMR Meeting - Florence 2010 Start: Thursday, End: Saturday (+ CMR exam)

A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.

Programme overview (subject to change)

Society for Vascular Surgery Vascular Annual Meeting Boston, MA June 20-23, 2018 SCHEDULE OF EVENTS. (as of 3/26/18)

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

Correlation of novel cardiac marker

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Nordic-Baltic Region University Research Course Gdańsk, Poland, September 19-21, 2019

PCSK9 Inhibitors and Modulators

The Israeli Society for Research, Prevention & Treatment of Atherosclerosis

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)

Women & Heart Disease Prevention

PROGRAMME. 8th INTERNATIONAL CONFERENCE ON PAEDIATRIC CONTINUOUS RENAL REPLACEMENT THERAPY (pcrrt)

CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018

ATP IV: Predicting Guideline Updates

Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Controversies in Cardiac Pharmacology

CENTER FOR CONTINUING & OUTREACH EDUCATION. 30 Bergen St. ADMC 710 Newark, NJ

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Program. Introduction to Echocardiography for Congenital Heart Disease Chair: Ching Kit Chen, Singapore

Title: Statins for haemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D study.

Visegrád, Hungary, February 22-25, 2018

Professional International Study Management

European Academy of Paediatrics 2017 Congress and MasterCourse (EAP 2017) Preliminary Programme * As of August 18, Thursday, October 12, 2017

PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Thursday, December 7 th, 2017, 13:00 14:30

Seung-Hwan Lee, M.D., Ph.D.

Best Lipid Treatments

Society for Vascular Surgery Vascular Annual Meeting Boston, MA June 20-23, 2018 SCHEDULE OF EVENTS. (as of 3/05/18)

DECLARATION OF CONFLICT OF INTEREST. None

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Timothy Malins, MD, FACC Governor, New York Chapter, American College of Cardiology President, New York Cardiological Society

The Cardiac Patient from Birth to Adulthood February 2019 in Stockholm Sweden

COPD COPD and Lungs B2B Participation. 9 th International Conference on. March 11-12, 2019 Singapore

Tentative Program. 29th World Cardiology Conference. Speaker slots available. conferenceseries.com.

ESPACOMP SCIENTIFIC MEETING PROGRAM

1. Which one of the following patients does not need to be screened for hyperlipidemia:

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Transcription:

THURSDAY, 30 JUNE, 2016 18:00 18:30 OPENING CEREMONY Opening Lecture: TBA 18:30 19:30 Chairs: Maciej Banach (); Nathan D. Wong (Irvine, USA) 19:30 Get Together Reception FRIDAY, 1 JULY 2016 08:30 - Plenary Chairs: Nanette Wenger (Atlanta, USA), Maciej Banach () Cardiovascular Disease Risk Assessment in Older Adults 08:30 09:15 Nathan D. Wong Irvine, USA Prevention of CVD in the Elderly should begin before we are Elderly 09:15 10:00 Allan Sniderman Montreal Canada 10:00 10:30 Tea/ Coffee Break 10:30 LIPID Lowering Therapy 10:30 Diabetes and its complications 10:30 11:00 Chair: Allan Sniderman (Montreal Canada) Treatment of dyslipidemia in elderly patients with coronary heart disease: there are miles to go before we sleep. Peter P. Toth Chicago, USA Chair: Adrian Covic (Iasi, Romania) 10:30 11:00 Novel therapies for type-2 diabetes in pre-elderly and the elderly. Manfredi Rizzo Palermo, Italy

11:00 11:30 12:00 12:30 Statins and cardiovascular prevention in the elderly Dimitri P. Mikhailidis London, UK PCSK9 inhibitors for elderly patients? Another lack of evidence or effective therapy for older adults with high CV risk? Maciej Banach 12:00-12:30 12:30 14:00 Lunch 11:00 11:30 The Differential Effect of Atherosclerosis on End Organ Damage in adults and elderly patients with CVRF. Which group is on the highest risk of MI and stroke? Reuven Zimlichman Tel-Aviv, Israel HF management in the elderly Chair: Peter P. Toth (Chicago, USA) Nutraceuticals Chair: Corina Serban (Birmingham, AL, USA/) Blood pressure lowering and prevention of heart failure Alberto Zanchetti Milan, Italy COPD as a co-morbidity of HF. in elderly patients. Mitja Lainscak Celje, Slovenia Clinical impact of muscle wasting in heart failure. Stephan von Haehling Berlin, Germany Nutraceuticals in Lipid-Lowering Treatment. Manfred Rizzo Palermo, Italy Role of micronutrients and nutraceuticals in chronic heart failure. Daniel Pella Kosice, Slovak Republic 15:30 16:00 Tea/ Coffee Break, Exhibition and Poster Viewing 16:00 17:30 16:00-16:30 16:30 17:00 Lipids Chair: Manfredi Rizzo (Palermo, Italy) Irrefragable Evidence ApoB is a better marker of cardiovascular risk than LDL-C of non-hdl-c. Allan Sniderman, Montreal, Cananda Lipid Disorders therapy in older adults without cardiovascular disease. What do we know? Karam Kostner, 16:00 17:30 16:00 16:30 Renal Disease Chair: Lucian Petrescu () Effective Hypertension in older adults with chronic kidney disease. Many missing links? Jacek Rysz Dialysis modality choice in elderly patients with end-stage renal disease. Adrian Covic Iasi, Romania

Queensland, Australia 17:30 18:00 Non Cardiac Arterial disease and lipids in the elderly. Dimitri P. Mikhailidis London, UK SATURDAY, 2 JULY 2016 Plenary Chairs: Alberto Zanchetti (Milan, Italy), Franz Messerli (NY, USA) Clinical Pearls: Diagnostic Dilemmas in Cardiovascular Disease at Elderly Age. 08:30 09:15 Nanette Wenger, Atlanta, USA Hypertension Control in Older Adults: Implications of New US Guidelines and the SPRINT Trial 09:15 10:00 Nathan Wong Irvine, CA, USA 10:00 10:30 Tea/ Coffee Break, Exhibition and Poster Viewing 10:30 11:00 Stroke / Hypertenstion 10:30 11:00 Cardiovascular Interventions Chair: Maciej Banach () Chair: Stephan von Haehling (Berlin, Germany) 10:30-11:00 Hypertension Facts, Fiction and Follies Franz Messerli New York, USA 10:30-11:00 Percutaneous coronary Interventions in elderly. When, whom, how? What about novel methods, including bioresorbable stents? Daniel Brie 11:00 11:30 CHD in older adults in the 21 st century; findings from the REGARDS-MI study. Monika Safford Birmingham, AL, USA 11:00 11:30 Monoamine oxidase contribution to cardiovascular dysfunction in coronary patients undergoing surgical revascularization. Danina Muntean 12:30 14:00 Lunch 13:30 14:00 Special lecture: How to write a paper! Dimitri P. Mikhailidis, London, UK

Challenges in Elderly Chair: Monika Safford (Birmingham, AL, USA) The Healthy Aging Research Centre (HARC) Session Chair: Nanette Wenger (Atlanta, USA) Cardiovascular Prevention at Elderly Age Is it Ever Too Late? Nanette K. Wenger Atlanta, GA, USA Depression and CVD risk in the elderly Tomasz Sobow 14: 30-15:00 How to decrease heart dysfunction with suitable therapy of pulmonary diseases. Wojciech Piotrowski Aging, and Physical activity, and cardiovascular prevention? Tomasz Kostka 15.30 17.00 Therapy challenges Chair: Dimitri P. Mikhailidis (London, UK) 15.30 17.00 Arrythmias prevention and therapy Chair: Daniel Pella (Kosice, Slovak Republic) 15.30-16.00 16.00-16:30 16:30-17.00 Polypharmacy and polypragmasy in elderly cardiovascular patients. Daniel Pella Kosice, Slovak Republic Statin therapy in elderly. From lack of EBM, statin intolerance to quality of life. Maciej Banach 15.30-16.00 16.00-16:30 16:30-17.00 Supraventricular arrhythmias management in the elderly. 2016 state of knowledge. Daniel Lighezan Antithrombotic therapy in the elderly patients Lucian Petrescu 17.00 17.30 Tea/ Coffee Break, Exhibition and Poster Viewing 17.30 18:00 Closing